Clinical Trial Update: Temodar and Sutent as Therapy for Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating temozolomide (Temodar) and sunitinib (Sutent) for metastatic malignant melanoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Sutent (sunitinib)
• Temodar (Temozolomide)

Snippet

Sponsor: Northern California Melanoma Center | Conditions: Metastatic Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED